Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Shares Outstanding (Weighted Average) (2016 - 2025)

IGC Pharma (IGC) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $86.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 14.15% to $86.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $86.8 million, a 14.15% increase, with the full-year FY2025 number at $76.5 million, up 30.04% from a year prior.
  • Shares Outstanding (Weighted Average) was $86.8 million for Q3 2025 at IGC Pharma, up from $83.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $86.8 million in Q3 2025 to a low of $42.0 million in Q1 2021.
  • A 4-year average of $64.7 million and a median of $63.7 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 6.26% in 2021, then surged 39.97% in 2024.
  • IGC Pharma's Shares Outstanding (Weighted Average) stood at $51.1 million in 2021, then grew by 24.82% to $63.7 million in 2023, then increased by 21.82% to $77.6 million in 2024, then increased by 11.76% to $86.8 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Shares Outstanding (Weighted Average) are $86.8 million (Q3 2025), $83.0 million (Q2 2025), and $76.5 million (Q1 2025).